# 1 Efficacy and safety of Andrographis paniculata extract in patients with

# 2 mild COVID-19: A randomized controlled trial

- 3
- 4 Kulthanit Wanaratna<sup>a</sup>, Pornvimol Leethong<sup>b</sup>, Nitapha Inchai<sup>a</sup>, Wararath Chueawiang<sup>a</sup>,
- 5 Pantitra Sriraksa<sup>a</sup>, Anutida Tabmee<sup>a</sup>, Sayomporn Sirinavin<sup>c</sup>
- 6
- <sup>7</sup> <sup>a</sup>Department of Thai Traditional and Alternative Medicine, Ministry of Public Heath,
- 8 Thailand
- 9 <sup>b</sup>Samutprakarn Hospital, Ministry of Public Heath, Thailand
- <sup>10</sup> <sup>c</sup>Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine
- 11 Ramathibodi Hospital, Mahidol University, Thailand
- 12
- 13
- 14
- 15 Corresponding author:
- 16 Kulthanit Wanaratna, MD.
- 17 Department of Thai Traditional and Alternative Medicine
- 18 Ministry of Public Heath, Thailand
- 19 E-mail: kulthanitw@gmail.com

20

#### ABSTRACT

Objectives: To assess the efficacy and safety of *Andrographis paniculata* extract (APE)
 in adults with mild COVID-19.

Methods: Sixty-three adults aged 18-60 years, without co-morbidity, with laboratoryconfirmed mild COVID-19, were randomized 1:1 to receive APE (60 mg andrographolide, t.i.d, for 5 days) or placebo within 24 hours after admission, plus standard supportive care. The outcomes were clinical recovery rates by Day 5 using self-assessment scores, pneumonia by chest X-rays, nasopharyngeal SARS-CoV-2 detection by rRT-PCR on Day 5, changes of serum CRP levels, and adverse drug reactions. Chest X-rays and blood tests for CRP, liver and renal function, were performed on Days 1, 3, and 5.

**Results:** Baseline characteristics of patients in the APE-treatment (n=29) and placebo-30 31 control (n=28) groups were comparable. None had self-assessment scores showing complete clinical recovery by Day 5. Pneumonia occurred in 0/29 (0%) versus 3/28 32 (10.7%), (p=0.112). On Day 5, patients with SARS-CoV-2 detection were 10/29 (34.5%) 33 versus 16/28 (57.1%), (p=0.086); patients with CRP >10 mg/L were 0/29 (0%) versus 34 5/28 (17.9%), (p=0.023), for APE-treatment and placebo-control groups, respectively. All 35 36 three patients with pneumonia had substantially rising serum CRP; and high CRP levels 37 on Day 5. None had evidence of hematologic, hepatic or renal impairment.

Conclusion: Even though the study was limited by small sample size, our findings
 suggested promising efficacy and safety of the APE-treatment regimen in adults with mild
 COVID-19. Further studies, with adequate power to assure these findings, are required.

Keywords: Andrographis paniculata; COVID-19; SARS-CoV-2; randomized controlled
 trial; C-reactive protein; pneumonia

43

## Introduction

Coronavirus disease 2019 (COVID-19), caused by the novel severe acute 44 respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic of 45 46 the highest priority (World Health Organization, 2021). Clinical spectrum of the disease is categorized into asymptomatic, mild, moderate, severe, and critical illness. About 80% of 47 cases are classified as asymptomatic and mild (fever or upper respiratory tract symptoms, 48 49 malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste or smell, but without pneumonia), or moderate (pneumonia, with oxygen saturation >94% on room air). 50 Mild COVID-19 may worsen to moderate and severe disease, while pneumonia is the 51 52 primary indicator of more severe disease progression alongside multiple organ dysfunction or failure (Wu and McGoogan, 2020; National Institute of Health USA, 2021). 53 Predictors of a worse outcome in COVID-19 patients include host factors (e.g., 54 gender, age, co-morbidities), disease characteristics (Wu and McGoogan, 2020; National 55 Institute of Health USA, 2021), and laboratory parameters such as C-reactive protein 56 57 (CRP), which is an inflammatory marker (Mueller et al., 2020; Potempa et al., 2020; Wang, 2020; Stringer et al., 2021). In normal healthy individuals, baseline CRP levels in 58 59 the blood are reported to be less than 10 mg/L (World Health Organization, 2014; Wang, 60 2020). The main mechanisms of disease progression in COVID-19 are intracellular viral replication causing cell lysis or cell death, and hyperactivation of immune responses 61 contribute to widespread hyperinflammation (van Eijk et al., 2021). In addition to 62 symptomatic management of patients with COVID-19, a therapeutic drug that would limit 63

64 the course of infection is urgently needed.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.08.21259912; this version posted August 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

65 Andrographis paniculata (Burm.f.) Nees is an annual herb native to the Indian subcontinent and widely introduced, naturalized, and cultivated in Southeast Asia and 66 China (Kew Science, 2019). It is one of the commonly used medicinal plants in Indian 67 Ayurvedic medicine, Chinese and Thai traditional medicines, for the treatment of acute 68 upper respiratory tract infection and diarrhea (National Drug Committee, Thailand 2000; 69 The State Pharmacopoeia Commission of the People's Republic of China, 2015; 70 Banerjee et al., 2021). Its name in Thai is Fa Thalai Chon. The main constituent of A. 71 *paniculata* is and rographolide which is a bioactive diterpene lactone. The therapeutic 72 efficacy of A. paniculata is due to its various pharmacological activities, i.e., antiviral, anti-73 inflammatory, antipyretic, and immune regulation activities (Dai et al., 2019; Hossain et 74 al, 2021). The adverse effects include headache, fatigue, allergic reactions, nausea, 75 diarrhea, and mild hypotension, which are uncommon; while more severe adverse effects, 76 although very rare, are urticaria or anaphylaxis (Thamlikitkul et al., 1991; Suriyo et al, 77 2017; Worakunphanich et al., 2021). 78

In silico studies revealed that andrographolide is an inhibitor of the main protease of SARS-CoV-2 which leads to prevention of viral replication (Murugan et al., 2020; Shi et al., 2020; Enmozhi et al., 2021; Hiremath et al., 2021). Furthermore, *in vitro* study also demonstrated that it acts on SARS-CoV-2 by preventing viral replication in cells, especially in late phase of viral life cycle. (Phumiamorn S, 2020; Sa-Ngiamsuntorn et al., 2021). The treatment effects of APE were explored in a small group (n=6) of mild COVID-19 volunteers; clinical improvement and SARS-CoV-2 reduction were detected.

Therefore, this randomized, double-blind, placebo-controlled trial was conducted to determine the clinical and virological efficacy, and safety of oral *A. paniculata* extract

among adults with mildly symptomatic SARS-CoV-2 infection. Additionally, we explored
 the role of serum CRP in the prediction of disease progression in mild COVID-19.

90

### **Patients and Methods**

The study was conducted from December 2020 to March 2021, during the second COVID-19 epidemic wave in Thailand. During that period of time, anyone who tested positive for SARS-CoV-2, from nasopharyngeal swabs for real-time reverse transcription polymerase chain reaction (rRT-PCR) test, were promptly admitted to state quarantine hospitals. Samut Prakan Hospital and Nakhon Pathom Hospital, two state quarantine hospitals in central Thailand, were our study sites.

#### 97 **Patients**

The patient inclusion criteria were (1) age 18-60 years; with (2) diagnosis of 98 99 SARS-CoV-2 infection by positive rRT-PCR test; (3) being admitted to the hospitals within 100 72 hours of illness; (4) presence of any signs and symptoms of mild COVID-19 (e.g., fever, cough, sore throat, malaise, headache, and diarrhea); and (5) not having signs and 101 102 symptoms of pneumonia or abnormal chest imaging. Patients were excluded if they (1) 103 had any underlying medical conditions that increased the risk of severe COVID-19; (2) 104 had any conditions for which using A. paniculata should be avoided, i.e., history of allergy 105 to A. paniculata, taking antihypertensive or anticoagulant drugs, pregnancy or breastfeeding; or (3) were receiving any antiviral drug. On admission to the study hospitals, the 106 107 inclusion and exclusion criteria were verified. Patients were informed about the study project and those interested in study participation were requested to sign informed consent. 108

109

#### 110 Study treatment

The standardized alcoholic extract of the aerial part of A. paniculata (APE, AP 111 extract) was used. Both APE and placebo capsules were produced by Thai Herbal 112 Products Co., Ltd, Thailand, and both were indistinguishable. Each capsule of APE 113 contains 20 mg of andrographolide. The patients received either oral APE or placebo, 114 115 within 24 hours after admission (Day 1 of clinical trial), in addition to standard supportive care following the national clinical practice guideline. The APE-treatment patients 116 received 3 capsules (60 mg. andrographolide) of APE while the placebo-control patients 117 118 received 3 capsules of placebo, 3 times a day (t.i.d.), for 5 days.

#### 119 **Outcome assessment**

120 The primary outcomes were complete clinical recovery rates by Day 5. The 121 secondary outcomes included pneumonia development during the course of illness, SARS-CoV-2 detection, serum CRP levels, and adverse drug reactions. Clinical recovery 122 123 was self-assessed by the patients using visual analog scale (VAS) scores. Chest X-rays 124 were assessed on Days 1, 3, and 5 of the clinical trial. Additional chest X-rays were 125 performed for those without abnormal chest X-rays by Day 5, who had progression of 126 respiratory symptoms. Nasopharyngeal swabs were performed on Day 5 for the detection 127 of SARS-CoV-2 by rRT-PCR. Venous blood specimens were collected on Days 1, 3, and 5 for complete blood count, blood urea nitrogen and creatinine, aspartate 128 129 aminotransferase and alanine aminotransferase, and CRP. Suspected clinical adverse effects of drugs were recorded. 130

131

132

#### 133 Sample size

Sample size was calculated from the primary outcome with assumption that the duration of symptoms in mild COVID-19 was about 5 days and that the AP-treatment would cause 2-day decrease in duration. This led to an estimated sample size of 26 participants per group to provide type I error of 5% and type II error of 20%. The intended sample size was adjusted to 32 participants per group to compensate for possible dropout.

### 140 **Randomization and blinding**

The 1:1 randomization was prepared by a central researcher before participant 141 enrollment, by block randomization with a block size of six using a randomization 142 143 software. The randomization codes were labelled on APE or placebo packages which 144 were physically indistinguishable; each package contained 45 capsules of APE or placebo 145 for 5-day treatment of individual patients. The study hospitals were provided with code-146 labelled packages of APE or placebo. Each new participant was assigned the code on 147 the received drug package. The randomization code was kept secret from the clinic and 148 the participating investigators, and the code was revealed at the end of the study for 149 analysis.

#### 150 Statistical analysis

Data were described by mean with standard deviation (mean  $\pm$  SD) or frequency (%), and compared between groups by Student t-test for continuous data, Chi-square test or Fisher exact test for categorical data. All analyses were performed by STATA version 16.0, and p-value <0.05 was considered as being statistically significant.

155

### **Results**

Fifty-seven of the 63 enrolled patients completed the study, 29 patients in the APE-treatment group and 28 patients in the placebo-control group. Three patients of each group withdrew during the study, due to unwillingness for further blood testing (2 control, 2 APE-treatment) and unpleasant symptoms (1 palpitation in control, and 1 diarrhea in APE-treatment); while none of them developed pneumonia. The baseline characteristics (age, gender, body mass index, and CRP level on enrollment) were comparable between the 2 groups (Table1).

None of the participants had complete clinical recovery by Day 5 as determined by 163 patient self-assessed VAS scores, and further assessment was not performed according 164 165 to the protocol. Table 2 showed the numbers of patients with pneumonia, Day-5 detection of nasopharyngeal SARS-CoV-2, and CRP levels >10 mg/L in the two groups. None of 166 the patients in the APE-treatment group, but 3 patients in the placebo-control group 167 168 developed pneumonia (on Days 6-7), being 0/29 (0%) versus 3/28 (10.7%), (p=0.112). On Day 5, SARS-CoV-2 was detected from nasopharyngeal swab in 10/29 (34.5%) patients 169 of the APE-treatment group, and 16/28 (57.1%) patients of the placebo-control group, 170 171 (p=0.086).

172 None of the APE-treatment group had CRP >10 mg/L during the 5-day study 173 period. On admission, 2 patients in the placebo-control group had high CRP levels (18.3 174 and 18.4 mg/L), and one who had rising CRP levels developed pneumonia while another 175 with steady CPR levels did not. On Day 5, the proportions of patients with CRP >10 mg/L 176 were 0/29 (0%) in APE-treatment group, and 5/28 (17.9%) in placebo-control group, 177 (p=0.023). Three patients who had pneumonia had substantially rising serum CRP on

Day 3 and high CRP of 13.9, 20.7, and 21.0 mg/L on Day 5. In addition, 2 patients in the placebo-control group had rising CRP and high CRP of 16.0 and 16.1 mg/L on Day 5, but did not have pneumonia.

Abnormal symptoms as possible AP adverse effects were found in 2 patients in the APE-treatment group, and both were mild and self-limited gastrointestinal tract symptoms (1 diarrhea), and one patient in the placebo-control group had palpitation. None of the patients in both groups had laboratory evidence of hematologic, hepatic or renal function impairment.

186

## Discussion

The study of the efficacy of APE-treatment on the primary outcome, as clinical 187 recovery rates by Day 5, could not give relevant information. However, our study suggests 188 189 that the regimen of APE treatment (oral 60 mg of andrographolide, t.i.d., for 5 days) given 190 early to adults with mild COVID-19, without risk for severe COVID-19 by host factors, has promising efficacy on mild COVID-19, though the sample size is too small to detect 191 statistically significant difference of outcomes. The study suggests a tendency of risk 192 reduction of pneumonia, more rapid SARS-CoV-2 clearance, and inflammation 193 194 suppression. The potential treatment benefit of APE on COVID-19 is likely to be the result 195 of the anti-SARS-CoV-2 and anti-inflammatory activities of andrographolide and its derivatives. Adverse effects from the treatment were found uncommon and benign. 196

A recent comprehensive review on antimicrobial pharmacology, clinical safety, and efficacy of *Andrographis paniculata*, demonstrated its high potential for effective and safe COVID-19 treatment, and there was a need for clinical evidence (Hossain et al., 2021). This study was performed on orally-administered APE in mild COVID-19 patients. A recent

study from China on injectable andrographolide (Xiyanping in Chinese) in mild to moderate
COVID-19 patients, demonstrated significant reduction of the time to cough relief, fever
resolution and virus clearance, and less patients experienced disease progression to the
severe stage. (Zhang et al., 2021).

The second epidemic wave of SARS-CoV-2 in Thailand lasted between December 206 2020 and March 2021, the duration which covered the study period. Using the whole 207 genome sequencing, it was found that approximately 90% of the strains, circulating in the 208 study area during that period, belonged to the B.1.36.16 lineage (COVID-19 Network 209 Investigations Alliance, 2021). Considering that the treatment effects of andrographolide 200 may vary with different SARS-CoV-2 strains, further exploration is therefore needed.

Three patients who had pneumonia had substantially rising serum CRP on Day 3 211 212 and high CRP of 13.9, 20.7, and 21.0 mg/L on Day 5. These findings of this study on serum CRP levels in mild COVID-19 patients agree with the previous retrospective study 213 in 27 adults in the early stage of COVID-19 that CRP levels were low in mild disease and 214 increased with disease progression (Wang, 2020). A study reported that increasing CRP 215 levels during the first 48-to-72 hours of hospitalization was a better predictor of respiratory 216 217 deterioration than initial CRP levels, while steady CRP levels were observed in patients whose condition remained stable (Mueller et al., 2020). 218

The proportions of the 3 secondary outcomes (pneumonia, viral detection, CRP) in the 2 compared groups of this trial suggested benefit of APE-treatment in mild COVID-19. A statistically non-significant difference ( $p \ge 0.05$ ) in this underpowered study does not imply that the treatment is not clinically effective (Tsang R, 2009).

223

224

## Conclusions

This double-blind RCT, in adults with mild COVID-19 and without risk factors for severe disease, suggested promising effects of the oral APE-treatment regimen on the prevention of pneumonia, shortening of viral shedding period, and inflammatory suppression. Adverse drug reactions were mild, self-limited, and uncommon. The study was limited by the small sample size. Further studies, with adequate power to assure conclusions, are required.

231

### Acknowledgments

The authors gratefully acknowledge the study team, at Samut Prakan Hospital and Nakhon Pathom Hospital, who involved in this study; the Department of Medical Science, Ministry of Public Health (MOPH), for virological study; Dr. Marut Jirasetsiri and Dr. Amporn Benjaponpitak, Department of Thai traditional and Alternative Medicine, MOPH, for their full encouragement and support. We would like to thank Stephen John Pinder and Dr. Anchalee Chuthaputti for conducting a language review on this manuscript.

Financial support. This research project was supported by Thai Traditional MedicalKnowledge Fund.

Potential conflicts of interest. The authors have no conflicts of interest to declare.

Ethics approval and consent to participate. Ethical approval was obtained from the
Ethics Committee for Research in Human Subjects in the Fields of Thai Traditional and
Alternative Medicine (No.12-2563). All participants gave written informed consent.

244

245

246	References
247	[1] Banerjee S, Kar A, Mukherjee PK, Haldar PK, Sharma N, Katiyar CK.
248	Immunoprotective potential of Ayurvedic herb Kalmegh (Andrographis paniculata)
249	against respiratory viral infections - LC-MS/MS and network pharmacology analysis.
250	Phytochem Anal. 2021;32:629-39. https://doi.org/10.1002/pca.3011.
251	[2] COVID-19 Network Investigations (CONI) Alliance. Genomic epidemiology of novel
252	coronavirus - Thailand-focused subsampling. Available from:
253	https://nextstrain.org/community/fai-k/coni/Thailand?c=pango_lineage&l=scatter.
254	(Accessed: 22 July 2021).
255	[3] Dai Y, Chen SR, Chai L, Zhao J, Wang Y, Wang Y. Overview of pharmacological
256	activities of Andrographis paniculata and its major compound andrographolide.
257	Crit Rev Food Sci Nutr. 2019; 59: S17-S29.
258	https://doi.org/10.1080/10408398.2018.1501657.
259	[4] Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor
260	of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn. 2021;39:
261	3092-3098. https://doi.org/10.1080/07391102.2020.1760136.
262	[5] Hiremath S, Kumar HDV, Nandan M, Mantesh M, Shankarappa KS,
263	Venkataravanappa V, et al. In silico docking analysis revealed the potential of
264	phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used
265	in Ayurveda medicine in inhibiting SARS-CoV-2. 3 Biotech. 2021;11: 44.
266	https://doi.org/10.1007/s13205-020-02578-7

267	[6] Hossain S, Urbi Z, Karuniawati H, Mohiuddin RB, Moh Qrimida A, Allzrag AMM, et
268	al. Andrographis paniculata (Burm. f.) Wall. ex Nees: An updated review of
269	phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy. Life.
270	2021;11(4):348. https://doi.org/10.3390/life11040348
271	[7] Kew Science. Plant of the World Online. Andrographis paniculata (Burm.f.) Nees.
272	http://www.plantsoftheworldonline.org/taxon/urn:lsid:ipni.org:names:45226-1.
273	(Accessed: 24 June 2021).
274	[8] Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al.
275	Inflammatory biomarker trends predict respiratory decline in COVID-19 patients.
276	Cell Rep Med. 2020;1(8),100144. https://doi.org/10.1016/j.xcrm.2020.100144.
277	[9] Murugan NA, Pandian CJ, and Jeyakanthan J. Computational investigation on
278	Andrographis paniculata phytochemicals to evaluate their potency against SARS-
279	CoV-2 in comparison to known antiviral compounds in drug trials. J Biomol Struct
280	Dyn. 2020;16:1-12. https://doi.org/10.1080/07391102.2020.1777901.
281	[10] National Drug Committee. National list of essential drugs 1999 (List of herbal
282	medicine products). Bangkok: Agricultural cooperative federation of Thailand. 2000.
283	[11] National Institute of Health, USA. Clinical Spectrum of SARS-CoV-2 Infection.
284	https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. 2021
285	(Accessed: 13 June 2021).
286	[12] Phumiamorn S, Sapsutthipas S, Pruksakorn P, Trisiriwanich S. In vitro study on
287	antiviral activity of Andrographis paniculata against COVID-19.
288	https://www3.dmsc.moph.go.th/en/. 2020 (Accessed: 13 June 2021).

- [13] Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the
- 290 Use of C-Reactive Protein as a Diagnostic Index of Disease Severity in COVID-19
- <sup>291</sup> Infections. Am J Trop Med Hyg. 2020;103(2):561-63. DOI:10.4269/ajtmh.20-0473
- [14] Sa-Ngiamsuntorn K, Suksatu A, Pewkliang Y, Thongsri P, Kanjanasirirat P,
- 293 Manopwisedjaroen S, et al. Anti-SARS-CoV-2 Activity of Andrographis paniculata
- extract and its major component andrographolide in human lung epithelial cells and
- 295 cytotoxicity evaluation in major organ cell representatives. J Nat Prod. 2021;84:1261-
- 296 270. DOI:10.1021/acs.jnatprod.0c01324.
- [15] Shi TH, Huang YL, Chen CC, Pi WC, Hsu YL, Lo LC, Chen WY, Fu SL, Lin CH.
- Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-
- nCoV and SARS-CoV through covalent linkage. Biochem Biophys Res Commun
- 300 2020 533: 467-73. DOI:10.1016/j.bbrc.2020.08.086.
- [16] Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al.; COPE Study
- 302 Collaborators. The role of C-reactive protein as a prognostic marker in COVID-19.
- 303 Int J Epidemiol. 2021;50:420-29. DOI:10.1093/ije/dyab012.
- [17] Suriyo T, Pholphana N, Ungtrakul T, Rangkadilok N, Panomvana D, Thiantanawat
- A, et al. Clinical parameters following multiple oral dose administration of a
- 306 standardized Andrographis paniculata capsule in healthy Thai subjects. Planta
- 307 Med. 2017;83(9):778-89. doi: 10.1055/s-0043-104382.
- [18] Thamlikitkul V, Dechatiwongse T, Theerapong S, Chantrakul C, Boonroj P, Punkrut
- 309 W, et al. Efficacy of *Andrographis paniculata*, Nees for pharyngotonsillitis in adults.
- 310 J Med Assoc Thai.1991;74:437-42.

- [19] The State Pharmacopoeia Commission of the People's Republic of China.
- <sup>312</sup> Pharmacopeia of the People's Republic of China 2015. Andrographis Herba.
- Beijing, China: China Medical Science Press; 2015.
- [20] Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically
- 315 significant differences in adverse event rates in randomized controlled trials, J Clin
- Epidemio, 2009; 62(6): 609-16. https://doi.org/10.1016/j.jclinepi.2008.08.005.
- [21] van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, et al.
- 318 COVID-19: immunopathology, pathophysiological mechanisms, and treatment
- options. J Pathol. 2021;254(4):307-31. DOI: 10.1002/path.5642.
- [22] Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect.
- 321 2020; 50:332-34. DOI:10.1016/j.medmal.2020.03.007.
- [23] WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (Accessed: 13
   June 2021).
- [24] Worakunphanich W, Thavorncharoensap M, Youngkong S, Thadanipon K,
- 325 Thakkinstian A. Safety of Andrographis paniculata: A systematic review and meta-
- analysis. Pharmacoepidemiol Drug Saf. 2021;30:727-39. DOI:10.1002/pds.5190.
- 327 [25] World Health Organisation. Vitamin and Mineral Information System. C-reactive
- 328 protein concentrations as a marker of inflammation or infection for interpreting
- biomarkers of micronutrient status. WHO/NMH/NHD/EPG/14.7 (Accessed: 13 June
- 330 2021)
- [26] Wu Z. and McGoogan JM. Characteristics of and important lessons from the
   coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of

- 333 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA.
- 334 2020; 323:1239-242. DOI: 10.1001/jama.2020.2648.
- [27] Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, et al. Efficacy and safety of
- 336 Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-
- label and randomized controlled trial. Phytother Res. 2021; 12:10.1002/ptr.7141.
- 338 DOI: 10.1002/ptr.7141.

339

# 341 **Table 1** Baseline characteristics of patients who received Andrographis paniculata extract

### 342 (AP extract) or placebo

Characteristics	AP extract	Placebo	p-value
	(n=29)	(n=28)	
Age (years), mean ± SD	39.3 ± 11.4	39.4 ± 11.6	0.949
Male, n (%)	12(41.4)	11 (39.3)	0.870
BMI (kg/m²), n (%)			
Underweight or normal weight	19 (65.5)	15 (53.6)	0.684
Overweight (BMI 25-29.9 kg/m <sup>2</sup> )	7 (24.1)	9 (32.1)	
Moderate Obesity (BMI <u>&gt;</u> 30-34.9 kg/m <sup>2</sup> )	3 (10.3)	4 (14.3)	
Severe Obesity (BMI <u>&gt;</u> 35 kg/m <sup>2</sup> )	0 (0.0)	0 (0.0)	
CRP levels on hospital admission, n (%)			
<u>≤</u> 5 mg/L	24 (82.8)	22 (78.6)	0.495
>5-10 mg/L	5 (17.2)	4 (14.3)	
>10-18 mg/L	0 (0.0)	2* (7.1)	

343 BMI = body mass index, CRP = C-reactive protein

\*One patient with rising CRP levels developed pneumonia, the other with steady CRP
levels did not.

- 347 **Table 2** The study outcomes in the groups of patients who received Andrographis
- 348 *paniculata* extract (AP extract) or placebo.

Outcomes	AP extract	Placebo	p-value
	(n=29)	(n=28)	
Pneumonia, n (%)	0 (0.0)	3 (10.7)	0.112
Positive SARS-CoV-2 on Day 5**, n (%)	10 (34.5)	16 (57.1)	0.086
CRP >10mg/L on Day 5**, n (%)	0 (0.0)	5* (17.9)	0.023

- 349 CRP = C-reactive protein
- 350 \*3 patients developed pneumonia
- 351 \*\*Day 5 of clinical trial